

Solubilized Gel Bests Combination Acne Tx

BY ROBERT FINN

A new preparation of 5% benzoyl peroxide solubilized in a gel proved better than a 5% benzoyl peroxide/1% clindamycin preparation for treating acne vulgaris, according to the results of a poster presented at the annual Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation.

Dr. Leon H. Kircik of Louisville, Ky.,

and his colleagues followed 65 patients who applied solubilized benzoyl peroxide (BPO) gel to one side of their face and BPO/clindamycin to the other side twice daily for up to 12 weeks.

The patients were aged 11-45 years and had moderate acne. The solubilized BPO gel was associated with a significant reduction in noninflammatory lesions, compared with BPO/clindamycin at weeks 1, 2, 3, 4, and 12. At week 12, for example,

the solubilized BPO gel was associated with a 57% reduction in noninflammatory lesions, compared with 46% for the BPO/clindamycin. There were no differences between the products in relation to the number of inflammatory lesions.

Levels of erythema, dryness, peeling, stinging/burning, and itching were reported more by patients with the solubilized BPO gel. While this difference was statistically significant, it was not

clinically significant, Dr. Kircik said in an interview. Because of these study results, "I use the solubilized BPO gel anytime I need a benzoyl peroxide," he said.

The new preparation is proprietary and is available commercially under the brand name SoluCLENZ Rx Gel from Obagi Medical. Dr. Kircik disclosed receiving research funding from the manufacturer.

SDEF and this news organization are owned by Elsevier. ■

Humalog® KwikPen®

The easy-to-use, easy-to-inject prefilled pen.*¹

- Small, lightweight, and portable
- Allows your patients to discreetly deliver Humalog®
- Does not need refrigeration after first use
- Easy to set the dose¹
- Short thumb-reach at high doses

(Actual size)



Please note:

When prescribing Humalog KwikPen, you will need to write a separate prescription for BD needles.

Humalog® KwikPen®

insulin lispro injection (rDNA origin)

Humalog (insulin lispro injection [rDNA origin]) is for use in patients with diabetes mellitus for the control of hyperglycemia. Humalog should be used with longer-acting insulin, except when used in combination with sulfonylureas in patients with type 2 diabetes.

Important Safety Information

Humalog differs from regular human insulin by its rapid onset of action as well as a shorter duration of action. Therefore, when used as a mealtime insulin, Humalog should be given within 15 minutes before or immediately after a meal. Due to the short duration of action of Humalog, patients with type 1 diabetes also require a longer-acting insulin to maintain glucose control (except when using an insulin pump). Glucose monitoring is recommended for all patients with diabetes.

The safety and effectiveness of Humalog in patients less than 3 years of age have not been established. There are no adequate and well-controlled clinical studies of the use of Humalog in pregnant or nursing women.

Starting or changing insulin therapy should be done cautiously and only under medical supervision.

Humalog is contraindicated during episodes of hypoglycemia and in patients sensitive to Humalog or one of its excipients.

Hypoglycemia

Hypoglycemia is the most common adverse effect associated with insulins, including Humalog. Hypoglycemia can happen suddenly, and symptoms may be different for each person and may change from time to time. Severe hypoglycemia can cause seizures and may be life-threatening.

Other Side Effects

Other potential side effects associated with the use of insulins include: hypokalemia, weight gain, lipodystrophy, and hypersensitivity. Systemic allergy is less common, but may be life-threatening. Because of the difference in action of Humalog, care should be taken in patients in whom hypoglycemia or hypokalemia may be clinically relevant (eg, those who are fasting, have autonomic neuropathy or renal impairment, are using potassium-lowering drugs, or taking drugs sensitive to serum potassium level).

For additional safety profile and other important prescribing considerations, see the accompanying Brief Summary of full Prescribing Information.

Please see full user manual that accompanies the Pen.

Humalog® is a registered trademark of Eli Lilly and Company. Humalog is available by prescription only.

Humalog® KwikPen® is a registered trademark of Eli Lilly and Company. Humalog KwikPen is available by prescription only.

* KwikPen Design Validation User Study included adult male and female participants with type 1 and type 2 diabetes. Of the total 150 study participants, 56 were insulin-naïve, 42 were currently administering insulin with a vial and syringe, and 52 were experienced insulin pen users.

Reference

1. Data on file, Eli Lilly and Company. KwikPen Design Validation User Study. HUM20071024A.

Also Available

Original
Prefilled Pen



Humalog® is also available by prescription in the **original Humalog Prefilled Pen.**

Find out more at www.humalog.com



Humanly possible.

Humalog®

insulin lispro injection (rDNA origin)

Lilly